Arzerra and Atrial fibrillation/flutter - a phase IV clinical study of FDA data

Summary:

Atrial fibrillation/flutter is reported as a side effect among people who take Arzerra (ofatumumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Methotrexate, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Atrial fibrillation/flutter when taking Arzerra. It is created by eHealthMe based on reports of 1,041 people who have side effects when taking Arzerra from the FDA, and is updated regularly.

What is Arzerra?

Arzerra has active ingredients of ofatumumab. eHealthMe is studying from 1,042 Arzerra users. Check the latest studies of Arzerra.

What is Atrial fibrillation/flutter?

Atrial fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles) is found to be associated with 2,366 drugs and 3,840 conditions by eHealthMe. Check the latest studies of Atrial fibrillation/flutter.

On May, 12, 2026

1,041 people reported to have side effects when taking Arzerra.
Among them, 56 people (5.38%) have Atrial fibrillation/flutter.

Could Arzerra cause Atrial fibrillation/flutter?

Among these 56 people:

How long have people been on Arzerra when they have Atrial fibrillation/flutter? *

What is the gender of people who have Atrial fibrillation/flutter when taking Arzerra? *

female: 0.0 %
male: 100 %

What is the age of people who have Atrial fibrillation/flutter when taking Arzerra? *

What are other drugs people take besides Arzerra? *

What are other side effects people have besides Atrial fibrillation/flutter? *

Thrombocytopenia (decrease of platelets in blood): 49 people, 87.50%
Febrile Neutropenia (fever with reduced white blood cells): 48 people, 85.71%
Haemorrhage (bleeding): 47 people, 83.93%
Anaemia (lack of blood): 47 people, 83.93%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 46 people, 82.14%
Infection: 42 people, 75.00%
Disease Progression: 16 people, 28.57%
Swallowing Difficulty: 5 people, 8.93%
Pneumonia: 5 people, 8.93%
Arrhythmias (irregular heartbeat): 4 people, 7.14%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 28 people, 50.00%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 23 people, 41.07%
Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 23 people, 41.07%
High Blood Cholesterol: 3 people, 5.36%
Rashes (redness): 2 people, 3.57%
Parkinson's Disease: 2 people, 3.57%
Pain: 2 people, 3.57%
Chronic Lymphocytic Leukaemia Refractory (a cancer of blood cells lymphocytes that no longer responds favourably to treatment): 2 people, 3.57%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 1.79%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 1.79%

* Approximation only. Some reports may have incomplete information.

Do you take Arzerra and have Atrial fibrillation/flutter?

- Check whether Atrial fibrillation/flutter is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arzerra:

Arzerra (1,042 reports)

Browse all side effects of Arzerra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Atrial fibrillation/flutter:

Atrial fibrillation/flutter (2,366 drugs)

Browse all the conditions that are associated with Atrial fibrillation/flutter:

Atrial fibrillation/flutter (3,840 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ofatumumab (the active ingredients of Arzerra) and Arzerra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.